Our History

2009

 

  • Delex Pharma was incorporated on July 13 and started its operations with Globo Asiatico Enterprises, Inc. as its mother company.
  • Delex Pharma focused its promotions in critical care hospital market where its leaders have more than 20 years of experience.
  • Manned only by a regulatory pharmacist and two skeletal sales force, Delex marketed two major products in GMA and Luzon: Buminate (Albumin 25%) of Baxter-Bioscience and Tramadol (Milador) Inj. of Sandoz Philippines.
  • Signed distribution & marketing agreements with United Biotech (India), ICU Medical Inc. (USA) & Innogene Kalbiotech (Indonesia).

2010

 

  • Delex Pharma increased its head count from a 3-man to a 19-man team in 2010.
  • Delex have forged marketing agreements with both national and multinational companies. The company was entrusted to distribute the original Nicardipine, Perdipine, from Astellas Pharma. After a year of marketing the product, it become a threat to Unilab’s Cardipine brand.
  • Furthermore, DPII was entrusted by Baxter to market & distribute its select critical care products, namely Flexbumin (Human Albumin), Premixed Potassium Chloride, and Premixed Dopamine. DPII was able to create and establish the market and was successful in introducing the concepts of Flexbumin in flexibag, and Potassium chloride in premixed form until the closure of Baxter Commercial in the Philippines in 2013.
  • Delex partnered with Janssen to promote Sublimaze, the innovator brand of Fentanyl Citrate. At that time, the brand was suffering from a major setback in terms of market share vs. competitors. Delex (Sublimaze) successfully regained leadership after two years of marketing the product.
  • Delex re-launched Totilac (Hypertonic Sodium Lactate) in 2010 from Innogene Kalbiotech. The molecule was a failure when it was marketed by another distributor in 2007, with a sales volume of only 37 bags for 2 years. Delex was able to turn the tables and eventually sold 5,500 bags in its first year of marketing the product.

 

2011

 

  • DPII expanded its product lines as the company continued to build a good reputation to its existing and new business partners.
  • DPII launched its own brand of Norepinephrine, Norepin, in three (3) SKUs, 2ml, 4ml & 10ml. Norepin became the company’s banner product and the trusted norepinephrine generic brand in the market.
  • In the same year, DPII also launched its own Dobutamine brand, Dobulex, to start up the company’s direction of establishing its own house brands to market in the hospitals.

 

2012

 

  • DPII expanded its product lines as the company continued to build a good reputation to its existing and new business partners.
  • DPII launched its own brand of Norepinephrine, Norepin, in three (3) SKUs, 2ml, 4ml & 10ml. Norepin became the company’s banner product and the trusted norepinephrine generic brand in the market.
  • In the same year, DPII also launched its own Dobutamine brand, Dobulex, to start up the company’s direction of establishing its own house brands to market in the hospitals.

 

2013

  • DPII’s entry into the anti-infectives business was realized by launching its first two antibiotic products  – Ceftazin (Ceftazidime) & Ceftrex  (Ceftriaxone), manufactured by United Biotech, India.
  • To strengthen the company’s concept-selling model, Delex launched Ifimol IV (Paracetamol) in 1g, aimed to convert the usage of clinicians from ampoule preparation to vial premixed. 
  • To complete its product offering in Anesthesia, Delex launched Lexofol (Propofol) from Ambica. Lexofol is one of the few Propofol brands in the market available in vial preparation
  • Delex started its TQM (Total Quality Management) Program aimed to establish internal policies and structure that will help streamline the company’s operations.
  • The company partnered with Toastmasters International to support training of its homegrown Managers that will help hone their communication and leadership skills.

 

2014

 

  • Delex partnered with PWC as its designated external auditor to bring in structure and control to Delex finances based on international standards.
  • Midazolex, from Myungmoon Pharma in Korea, was launched to provide Anesthesiologists an alternative choice in Midazolam I.V./I.M.
  • Delex takes seriously its involvement in the community, thus, DPI partnered with World Vision to send 50 students as scholars.
  • Sandoz partnered with Delex to launch their generic brand of Fentanyl patch, Fendermal.
  • To augment DPII’s presence in the device business, the company launched TEGO, the first and only needlefree connector US FDA-cleared for use in hemodialysis applications.
  • Delex launched Claris’ antibiotic products – Spectrax (Cefipime) and Bacimycin (Clindamycin), to complete the company’s antibiotic franchise.
  • To intensify product inclusion in Mercury Drug Corp. outlets and expand the business of Delex, the company hired a consultant that will further drive Delex business in this distribution channel.

 

2015

 

  • The company launched its Leadership Training Program for high-potential employees through “Delex University”.
  • To strengthen the company’s training program, Delex forged partnership with San Beda College that will provide on-site MBA program to Delex Managers in preparation for their future roles and responsibilities in the company.
  • Delex purchased a 360-square meter property in Brgy. Sauyo, Quezon City, to house its growing business.
  • IMS captured DPII’s growth in the industry, ranking 42nd in the top 100 corporations based on hospital index.
  • The company strengthened its I.T. infrastructure to respond to the company’s growing need for information management system.
  • To increase DPII’s presence in the hospital device business, the company partnered with Smiths Medical to bring into the market their ambulatory infusion pump, CADD Legacy and its consumables.
  • Delex partnered with RBC to distribute its products as the company aimed to focus its efforts in marketing, and in building its house brands.

 

2016

 

  • The company restructured its marketing direction to advance its business in Critical Care, Anesthesia and Device, where Delex’s competencies are.
  • This is the first time in DPII’s six years of existence that all products being marketed DPII house brands.
  • Delex boldly decided to handle the distribution of its products, with the goal of improving customer reach and service to ultimately achieve customer satisfaction.
  • As Delex Leaders have seen the importance of empowering their millennial employees, the company designated Fr. Peter Coching as SHIELD Director who will lead the Acculturation and Values Formation Program of the company towards its growing young employees.
  • Delex increased its scholars in World Vision, from 50 students to 80.
  • Delex is about to complete its processes, protocols and SOPs to establish structure to company’s business operations.

 

Lot 4 Blk 4 Carnation Street Corner Magnolia Street Barangay Sauyo Novaliches Quezon City Philippines.

Trunk Lines # 024260270 / 024260271
Fax # 6969835 /4553892
Globe # 09178703384/09175468547
Smart # 09989876472
Sun # 09257107617
Mon. – Fri., 8 AM – 5 PM
Closed Saturday and Sunday